Slide 1: Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine
Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized Polymeric Delivery System. Jean D Boyer VP Researc h & Development Vaccine Summit 2023 November 13-15, 2023 Boston, Massachusetts, USA © 2022 IMUNON Inc. PAGE 1
Slide 2: DNA Vaccines are Well-Suited to Overcome the Limitations of Current Vaccines
DNA Vaccines are Well-Suited to Overcome the Limitations of Current Vaccines • Longer duration of antigen expression/exposure • Induction of cellular and humoral responses • Strong T-cell responses • Stability at > 4O C • Flexible manufacturing © 2022 IMUNON Inc. PAGE 2
Slide 3: PLACCINE – A Novel DNA Vaccine Technology
PLACCINE – A Novel DNA Vaccine Technology Relies on Synthetic Delivery Systems: Non viral, non device, non-LNP Covalently-functionalized amphilphilic polymer delivery system • Dispersion • Gene Expression Formulated DNA • Protection X X • Membrane Interaction • Immunogenicity • Adjuvant Backbone X-
Slide 4: DNA Protection & Enhanced Gene Expression by PLACCINE Delivery System
DNA Protection & Enhanced Gene Expression by PLACCINE Delivery System Gene Expression: 10-15-fold > Naked DNA Protection of DNA Degradation 24 hours 7 days Luciferase (RLU/mg protein) Non-functionalized Functionalized 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Naked Lot#1 Lot#2 DNA PLACCINE System Degraded DN
Slide 5: Induced Immune Responses Capable of Suppressing Viral Replication
Induced Immune Responses Capable of Suppressing Viral Replication Protection in K18-hACE2 transgenic mice against SARS-CoV-2 infection D614G Log IC50 Titer 1.5 TNF IFN 1.0 0.5 0.0 PBS pVAC15 pVAC16 pVAC17 Delta CD8+ Tcells (%) © 2022 IMUNON Inc. PAGE 5
Slide 6: Comparable Protection to mRNA Vaccine in Monkeys
Comparable Protection to mRNA Vaccine in Monkeys Prototype Vaccines- Early SARS-CoV-2 Variants Bronchoalveolar Lavage IMNN-101 Prototype Vaccines 2 Days after Challenge 4 Days after Challenge 7 Days after Challenge Placebo Log Copies/ml pVac-15 (1, 1 mg) pVac-16 (2, 2 mg) pVac-15 (5, 1 mg) mRNA (100
Slide 7: IMNN-101 Induces Immune Responses Post Injection that are boosted
IMNN-101 Induces Immune Responses Post 1 Injection that are boosted FDA VRBAC Recommends XBB.1.5 for the 2023/2024 Booster IgG nAbs 105 5 Log IC50 Titer Endpoint Titer 4 104 3 103 2 102 1 PBS 50 mg 100 mg PBS 50 mg 100 mg IMNN-101 IMNN-101 2000 T-cells SC/106 Cells 1500 1000 500 PBS IMNN-101 © 2022
Slide 8: CD8 and CD4 T-cell Responses in a Mouse Model
CD8 and CD4 T-cell Responses in a Mouse Model Prime & Boost CD4 CD4 T cells (%) TNF-a IFN-g IL-2 pVac-76 (mg) 50 100 CD8 CD8 T cells (%) pVac-76 (mg) 50 100 © 2022 IMUNON Inc. PAGE 8
Slide 9: PlaCCine Induces Robust Immune Responses Following a Single Injection
PlaCCine Induces Robust Immune Responses Following a Single Injection Cellular Immune Response Binding Antibody Titers Endpoint Titer SFC/106 cells © 2022 IMUNON Inc. PAGE 9
Slide 10: Stable at 4°C for at Least Months
Stable at 4o C for at Least 12 Months PlaCCine- Commercial advantage over mRNA vaccines • Vector: pVac-17 (D614G-Delta) IgG Response • Formulation: PlaCCine 1m 3m 6m 10 5 9m 12m 10 4 Endpoint Titer 10 3 10 2 4⁰C Storage 1 3 6 9 12 10 1 Months 10 0 4C h 4C h 4C h 4C 4C h h es es es es es Fr Fr Fr Fr
Slide 11: Stable at 37°C for at least 14 Days
Stable at 37o C for at least 14 Days PlaCCine- Commercial advantage over mRNA vaccines NS = 0.141 NS = 0.06 Day-7 Day-14 4o C 37o C 4o C 37o C 4o C 37o C 4o C 37o C © 2022 IMUNON Inc. PAGE 11
Slide 12: PlaCCine Vaccines
PlaCCine Vaccines Additional Pathogens • Flu • LASSA • Marburg • Monkeypox Active Vaccine Partnerships © 2022 IMUNON Inc. PAGE 12
Slide 13: PlaCCine Vaccines- Immunogenicity Against Additional Pathogens
PlaCCine Vaccines- Immunogenicity Against Additional Pathogens Marburg (Wistar Institute) Influenza (Wistar Institute) Lassa (NIH/NIAID) IgG IgG T-cell IFN-g MARV GP-binding 1500 IgG Titers c e l ls 6 1000 S F C /1 0 500 0 PBS pVac-68 pVac-69 pVac-70 *p <0.05 **p <0.01 T-cell T-cell ****p<0.001 T-ce
Slide 14: PLACCINE - A New Class of Prophylactic Vaccines
PLACCINE - A New Class of Prophylactic Vaccines • PLACCINE leverages the DNA advantages to achieve: • Durable humoral and cytotoxic immune responses • Multivalent vaccines for better vaccine breadth • Stability at working temperatures • Flexible manufacturing • Independence from virus or device prov
Slide 15: Acknowledgements
Acknowledgements Imunon • Khursheed Anwer • Ebony Gary • Subeena Sood • Nicholas Turi • Majed M. Matar • David Weiner • Jessica Kim • Meredyth Kinsella • Kempaiah Rayavara • Heinrich Feldmann • Olivia Signer • Kyle Rosenke • John Henderson • Tipih Thomas • Joseph Rogers • Austin Arnold • Jennifer S.
Slide 16: Thank You
T h a n k Yo u © 2022 IMUNON Inc. PAGE 16